NA Selank Amidate: a stabilized form of Selank studied for its enzymatic resistance
N-terminal acetylation and C-terminal amidation: two classic chemical modifications applied to Selank to extend its half-life in in vitro protocols.
Contents
NA Selank Amidate is a chemically modified variant of Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a heptapeptide derived from tuftsin. The interest in this form lies not in a new target, but in a methodological property: stability.
Two terminal modifications, one shared goal
The molecule combines N-terminal acetylation with C-terminal amidation. These two modifications, widely used in peptide chemistry, neutralize the free terminal charges that serve as anchor points for aminopeptidases and carboxypeptidases. The reported result is increased resistance to exopeptidase degradation and an extended in vitro half-life compared with the native form.
What the literature documents on native Selank
The mechanistic data available mainly concern the unmodified peptide. Studies (PMID 31625062, PMC5322660) describe modulation of hippocampal expression of BDNF and NGF, potentiation of GABAergic transmission without direct binding to the GABA-A receptor, and reduced cortisol levels in acute stress models.
What the stabilized form changes for a protocol
The N-acetylated and amidated version is studied as a more stable analog for in vitro protocols in neuroprotection, synaptic plasticity, and cytokine modulation (PMID 32621722). Greater stability means, in practical experimental terms, better-controlled effective concentration over the incubation period, and therefore reduced inter-assay variability.
Behavioral observations reported
In animal models (PMC5322660), the literature describes an anxiolytic profile without a sedative component, as well as reported effects on memory (PMID 31625062). These observations are documented for Selank and, in the available studies, are extrapolated to its stabilized analogs.
